other materials, e.g. in thermal and acoustic insulation, is being advised and asbestos prohibited for these purposes. A threshold limit value of 2 fibres/rnl for all types of asbestos other than the prohibited crocidolite is being imposed. Enforcement of the regulations and power to grant exemptions in certain specific situations rest with the District Head ofthe Labour Inspectorate, supported and advised by an advisory committee of medical and technical experts, representatives of worker's unions and employers.
JEAN W CUTHBERT
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Aldosterone-25 years on1
Twenty-five years ago the isolation and characterization of aldosterone as the most potent mineralcorticoid gave a renewed surge of interest in the adrenal cortex, which has yet to show signs of diminishing. The key figures in the work leading to the isolation were Sylvia A Simpson (subsequently Mrs Sylvia Tait) and James F Tait of the Middlesex Hospital Medical School. Particularly significant was their work with I E Bush (then at NIMR) which demonstrated that the hormone was secreted, and with T Reichstein, J V Euw, A Wettstein and R Neher of Basle, Switzerland, on the isolation and structure. A Wettstein and 0 Schindler of Ciba, Basle, then synthesized aldosterone. Much of this earlier work is summarized by Simpson & Tait (1955) , and references to the papers on aldosterone during this period will be found in their paper.
To honour the Taits and their achievements the Section of Endocrinology of the Royal Society of Medicine and the Society for Endocrinology jointly held a Symposium at the Middlesex Hospital Medical School to examine our present knowledge of aldosterone from many different points of view. Eight papers were presented by speakers from Britain, Switzerland, the United States and Australia. The Taits' Dale Lecture to the Society for Endocrinology, which will be about some of these topics, will be presented in May 1979, when they receive the Dale Medal ofthe Society for Endocrinology.
The meeting was opened (with Professor J Muller (Zurich) in the Chair) by a short intro- duction by the Taits. In this they drew careful attention both to the earliest pre-war studies, particularly those of 0 Wintersteiner and J J Pfiffner whose work led to what must have been a fairly good preparation of aldosterone, even in the 1930s, and also to the more recent work of J Luetscher, whose clinical studies led to the conclusion that aldosterone was present in human urine and was not merely of academic interest but a compound of significant clinical importance. The contributions of H Mason, E C Kendall, J W Conn, F C Bartter and J 0 Davies, who were not present, were also emphasized.
Evolution
The first paper was from the St Bartholomew's/ Queen Elizabeth College group, on comparative aspects of aldosterone and zona glomerulosa function. Reviewing all the work in this field it can be concluded that the formation of aldosterone and the l7-deoxycorticosteroids such as corticosterone is a characteristic of adrenocortical function virtually ubiquitous throughout the vertebrates, from the Elasmobranch and Teleost fish up to the mammals (although at the submammalian level aldosterone is not necessarily the only corticosteroid affecting salt and water metabolism). Only in mammals does an adrenal zone exist which secretes largely glucocorticoids, and which is almost exclusively controlled by ACTH. Such a zone, the zone fasciculata, appears to have arisen in evolutionary history at the same time as receptors in target organs evolved their high degree of specificity, conferring on steroids such as aldosterone and cortisol (or corticosterone) their characteristically more precise properties as mineralocorticoids and glucocorticoids.
Biosynthesis and secretion
This was followed by the paper of Dr R Neher (Basle), one of the co-authors on many of the original papers on aldosterone chemistry. He reviewed some of the early work which clearly defined the structure of aldosterone together with the current status of knowledge about the biosynthesis of aldosterone, Early workers, including the Taits themselves, showed that corticosterone is a good aldosterone precursor, and is converted to aldosterone first by hydroxylation at carbon atom 18,to yield 18-hydroxycorticosterone, which it was thought would then be acted upon by a dehydrogenase to yield aldosterone. Curiously this part of the pathway is far from securely established even now. 18-hydroxycorticosterone can be converted to aldosterone as can other related steroids with an oxygen function at C-18, such as 18-hydroxydeoxycorticosterone. However, the yields are not good under all circumstances, and indeed in some studies the 18-oxygenated steroids are considerably less well converted to aldosterone than corticosterone itself. This has led to speculation about the possibility that further intermediates may be involved, possibly through a second hydroxylation at C-18, to give 18-dihydroxycorticosterone, which would spontaneously be dehydrated to aldosterone (see also Ulick 1976). One possibility is that the steroids during this process exist in a steroid-O-M-enzyme complex, and for this reason exogenously added 18-hydroxycorticosterone may not be readily converted. As Dr Neher pointed out, if a dehydrogenation step were involved, a reverse transformation, of aldosterone to 18-hydroxycorticosterone, should also be demonstrable, but this has not been reported.
Dr K J Catt (Bethesda) followed with a description of his group's more recent studies on the role of angiotensin in stimulating aldosterone secretion and the relationship of its biological activity to adrenal receptor binding. They used isolated dog or rat zona glomerulosa cells in suspension, and with a number of angiotensin analogues they have shown that binding affinities closely parallel biological activity in stimulating aldosterone output. He and other participants in the course of the day find that the so-called angiotensin III (des-Asp I-angiotensin II) has no more activity than angiotensin II itself; indeed in their studies with rat cells it appears to be less active, because of degradation. From this and other evidence, including analysis of the peptides bound to glomerulosa cells in vivoand invitro,they have concluded that the heptapeptide is not an important or necessary intermediate in the action of angiotensin II on adrenal steroidogenesis. In dog cells, maximal aldosterone stimulation is achieved at just under 10-9M angiotensin, when there is only partial receptor occupancy. Unlike rat cells, dog cells show a decreased response at higher angiotensin II concentrations; this, curiously, is associated with a further increase in receptor occupancy. One of the fascinating aspects of their work, is that although the evidence strongly points to angiotensin as the major stimulant of the glomerulosa, its effects vary considerably with the sodium and potassium status of the animal. Sodium deficiency gives increased angiotensin binding, and increases its potency as an aldosterone stimulator: a high sodium intake has the reverse effect. High potassium in incubation media gives greater sensitivity to angiotensin, and low potassium has the reverse effect. In the case of sodium, the early increase in affinity of receptors to angiotensin and the later increase in receptor number during sodium depletion are due to the effect of angiotensin itself regulating its own receptors. However, the mechanism of action of potassium remains to be elucidated.
Actions
The fourth paper was by Dr I S Edelman (New York), who for many years has studied the mode of action of aldosterone, using the toad bladder model. Some years ago Dr Edelman was able to demonstrate that aldosterone action is mediated by the induction of synthesis of a protein in the target cell, called aldosterone induced protein (AlP). One of the problems which this leads to is to elucidate the function of such a protein or proteins. Three possibilities have been postulated. One, the 'sodium pump' theory, holds that the AlP stimulates the activity of the sodium pump (on the serosal side of the cell) directly. Secondly, AlP may be involved in the supply of ATP to the sodium pump: the 'metabolic theory'. Thirdly, AlP may enhance the permeability to sodium of the mucosal membrane, on the luminal side of the cell: the 'permease theory'. With regard to the 'sodium pump' theory, it has, been demonstrated that aldosterone 'in fact has no effect on Vmax of the system, or on pump sites, under usual conditions. Furthermore, the sodium pump has a uniquely high K... for ATP (millimolar, compared with micromolar for ATP in most other systems). Consequently the 'pump theory' does not seem to apply. What does seem to be important, however, is the supply of ATP itself. Aldosterone has no effect on the toad bladder preparation in the absence of metabolic substrate, but after stimulation with aldosterone, the addition of pyruvate enhances electrolyte movement with no latent period: thus the substrate is required not for AlP synthesis, but for its action. Both citrate synthase and malate dehydrogenase activities are increased in response to aldosterone stimulation, and it seems likely that citrate synthase in particular is one of the AlPs. Consequently the metabolic pathway is one of the key mechanisms in aldosterone response. However it also seems that apical membrane permeability is stimulated by aldosterone. Studies with amiloride, a specific inhibitor of apical Na" channels, and noise-frequency analysis indicate an effect of aldosterone on apical conductance. This effect appears to be mediated by modulation of energy metabolism.
Physiology
The afternoon session was chaired by Professor W S Peart. Dr J P Coghlan (Melbourne) discussed the work of the Howard Florey Institute on the control of aldosterone secretion, which for twenty years has been studied using the remarkable model pioneered by this group: sheep with adrenals autotransplanted to the neck. Drawing attention first of all to the clinical situations in man, in which aldosterone secretion is not correlated with known aldosterone stimulators, Dr Coghlan further examined the role of sodium status in modulating the effect of angiotensin II. With a constant angiotensin II infusion, aldosterone secretion still rises dramatically in response to sodium depletion, and is suppressed following sodium repletion. If the endogenous secretion of angiotensin II is held to a constant level within the sodium replete range, similar effects are seen on aldosterone with sodium depletion and repletion. In subtle contrast to the conclusion of Dr Catt's group, the Australians hold that angiotensin II can have only a permissive role: if there is no angiotensin II the gland cannot respond to sodium depletion; in the presence of angiotensin II, there is a good correlation between aldosterone secretion and sodium status. The increased sensitivity to angiotensin II with negative sodium status is a crucial feature of aldosterone control. In agreement with the work of Dr Catt's group, the Australians also believe that angiotensin III is of only minor physiological importance, but emphasize that there are other factors involving the central nervous system which playa role in the control of aldosterone secretion and sodium balance. To explain certain effects, e.g. as seen in idiopathic hyperaldosteronism, they believe that a further stimulant of aldosterone may still await isolation.
For their studies on the relationship of the reninangiotensin-aldosterone system to blood pressure, the experimental model favoured by Dr R E McCaa's group (Jackson, Mississippi) is the intact unanaesthetized dog. His work also emphasizes the discrepancies which may exist between angiotensin II, blood pressure and aldosterone secretion. Constant infusion of angiotensin II gives an initially large increase in aldosterone which later declines to a steady 100% increment. In sodiumdeficient dogs, propranolol gives a drop in renin activity and in blood pressure, but aldosterone increases as potassium is shifted from red blood cells; serum sodium is also increased. Inhibitory analogues of angiotensin II in sodium depletion give reduced blood pressure, and increased plasma renin activity, but aldosterone remains more or less constant. Nevertheless, in the presence of the angiotensin 1->11 converting enzyme inhibitors, SQ 20881 or SQ 14225, which reduce blood pressure, aldosterone is very greatly decreased. In normal rats, SQ 14225 has little effect on aldosterone, although it is greatly reduced in sodiumdepleted animals. In a series of animals with Goldblatt clips, ranging from one kidney benign to two kidney malign preparations, SQ 14225 gives reduced blood pressure, and aldosterone secretion, while plasma renin activity is increased. These experiments lead also to the conclusion that the initial effect of SQ 14225 on blood pressure is through loss of angiotensin II: the effect of increased sodium excretion, largely mediated through the decline in aldosterone, is slower.
Hypertension
Dr A Lever (Glasgow) was the first speaker to address directly the question of adrenocortical function in relation to hypertension in man, and particularly to examine the nature of essential hypertension. He drew attention to the point that in normal individuals there were positive correlations between plasma angiotensin II and aldosterone and between plasma or potassium and aldosterone, probably because angiotensin II and potassium control aldosterone. In conditions where aldosterone secretion is autonomous, as in Conn's syndrome, the reverse is true: aldosterone suppresses angiotensin II, and increases potassium excretion, and there is thus a negative correlation between these parameters. There is also in Conn's syndrome a positive correlation between plasma aldosterone and sodium, again the reverse of the normal situation. In secondary aldosteronism, caused for example by excess angiotensin II production, the correlates are similar to normals. In essential hypertension, aldosterone secretion is not abnormal, but the correlation between aldosterone and angiotensin II, while positive, is quite poor. Low renin hypertensives are probably part of the same group according to these workers. In contrast to Conn's syndrome, in hyperaldosterone secretion associated with adrenocortical micronodular hyperplasia, the correlation between aldosterone and angiotensin II is positive. Lever believes that essential hypertension may be a different part of the same disease, the only difference being that aldosterone is in the normal range. Otherwise both groups may show hyperplasia, both have weak correlation between angiotensin II and aldo sterone, in both the actual level of aldosterone for a given level of angiotensin II may be high, and both have normal exchangeable sodium. The puzzle remains why the correlation between aldosterone and angiotensin II should be so weak, since here the adrenal is if anything more than normally sensitive to angiotensin II stimulation.
The question of the nature of essential hypertension was further examined by the last speaker of the day, Dr J C'Melby (Boston). In contrast to the Glasgow group, Melby believes that low renin essential hypertension is a separate phenomenon, possibly caused or characterized by a number of features. These include a sodium-dependent blood volume expansion (populations with high sodium diets have high incidence of hypertension) reduced GFR (primary renal sodium retention), and mineralocorticoid (or hypertensinogenic) steroid excess. Other forms of low renin essential hypertension may arise from altered juxtaglomerular function, pressure natriuresis reset in the kidney, decreased fj-adrenergic activity, or through decreased vascular capacitance. The involvement of the adrenal cortex in a number of cases seems clear: hypertension can be reduced by the aldosterone antagonist spironolactone, or by inhibitors of steroidogenesis such as aminoglutethimide or trilostane. The question is: what is stimulating which steroid? One possibility mentioned by Coghlan is that further as yet uncharacterized adrenocortical stimulants may exist. Additionally, as yet uncharacterized steroids may be involved. Some relatively unfamiliar steroids have been studied by Dr Melby and his group: these include l8-hydroxydeoxycorticosterone and 16a,18-
Social and biological effects on perinatal mortality!
One of the more exciting growth areas today is preventive medicine. It is in the beginning of life that the prevention of death, disease and disability fancy and childhood, due to improvements in sanitation and housing as much as to medical care. Deaths in the perinatal period have proved more resistant because they are less directly influenced by environmental measures, and thus present a greater challenge to the medical profession. These deaths have now assumed a substantial importance in developed countries, both because they are dihydroxydeoxycorticosterone. Neither seems to fit the bill but Melby ;s careful to point out that hypertensinogenic activity and classical mineralocorticoid activity do not necessarily always go hand in hand. It seems most likely that the entire range of biologically active steroids produced by the adrenal cortex has not been recognized even now. The breadth ofthis symposium was thus remarkable: and the meeting highlighted, at least for this reviewer, the point that despite 25 years activity, certain fundamental problems about aldosterone remain. These include: how is aldosterone biosynthesized? What is the primary mode of its action? Do further, uncharacterized, factors exist which control aldosterone secretion? What is the relationship of aldosterone and the adrenal cortex to hypertension? No clear answers emerge, yet in posing these questions to perhaps a larger audience than normally listen to aldosterone papers, the symposium (whose proceedings will appear in a special edition of the Journal of Endocrinology) served a valuable function.
